Metrics Expands with Fast-Track Development Laboratory
PTSM: Pharmaceutical Technology Sourcing and Management
Metrics opens a new laboratory to support fast-track development of pharmaceutical products in North Carolina.
Metrics is opening a new laboratory to better support fast-track development of pharmaceutical products in Greenville, NC. The new $1.6 million, 4,524 ft2 facility provides additional flexibility for early formulation and analytical method development. The facility is designed for preclinical development of early formulation prototypes and related analytical methods. In this laboratory setting, formulators and chemists will have significant autonomy to conduct development activities more quickly, according to the company.
The new processing suites will have independent HVAC systems and engineering controls such as interlocking airlock doors, room air pressure differentials, high-volume room air turnover, and 100% HEPA air filtration.The ground floor of the new facility consists of five processing rooms and one analytical laboratory. The second floor consists of workstations, office space, and a conference room. The new facility was expected to be fully operational by mid-February.
Source:
Metrics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
